<DOC>
	<DOCNO>NCT01666977</DOCNO>
	<brief_summary>The purpose phase 1b/2 study estimate treatment effect study drug measure progression free survival .</brief_summary>
	<brief_title>Phase 1b/2 Trial AMG386 With Pemetrexed Carboplatin Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>To evaluate incidence adverse event clinical laboratory abnormality define dose-limiting toxicity subject metastatic non-squamous non-small cell lung cancer ( NSCLC ) treat AMG 386 combination pemetrexed carboplatin</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Trebananib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically confirm , unresectable stage IV nonsquamous non small cell lung cancer ( NSCLC ) Radiographically evaluable disease ( measurable nonmeasurable ) per RECIST 1.1 modification Adequate hematological , renal , hepatic function , normal coagulation profile , calculate CrCL â‰¥ 45 mL/min Other criterion may apply Any prior chemotherapy target therapy nonsquamous NSCLC Subjects adenosquamous histology histology subtype contain great 10 % squamous cell Subjects epidermal growth factor receptor ( EGFR ) mutation sensitive treatment tyrosine kinase inhibitor ( TKI ) Subjects know anaplastic lymphoma kinase ( EML4ALK ) translocation History presence central nervous system metastases Central ( chest ) radiation therapy within 28 day prior enrollment/randomization , radiation therapy site ( ) within 14 day prior enrollment/randomization History pulmonary hemorrhage gross hemoptysis within 6 month History arterial venous thromboembolism within 12 month History clinically significant bleeding within 6 month Clinically significant cardiovascular disease within 12 month Other criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>